ReviewiMetaOmics2026
Bile acid metabolism and signaling in human and animal health: A One Health perspective.
Review in iMetaOmics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The One Health concept emphasizes the interdependence of human, animal, and ecosystem health. Against this broad backdrop, bile acids (BAs), as central products of host-microbiota co-metabolism, act far beyond their classical role in lipid emulsification. This review systematically summarizes BA biosynthesis, enterohepatic circulation, and gut microbiota-mediated metabolic modification. We highlight how gut microbiota-derived secondary BAs and farnesoid X receptor and Takeda G protein-coupled receptor 5-mediated BA signaling together shape BA homeostasis, glucose and lipid metabolism, intestinal barrier integrity, and immune homeostasis. We further discuss how population diversity, circadian rhythm, diet, behavior, environmental exposure, and surgical interventions dynamically shape systemic BA profiles. Finally, from a One Health perspective, we highlight the translational potential of BA-targeted strategies in hepatobiliary diseases, metabolic disorders, neurodegenerative and retinal degenerative diseases, and intestinal infections, as well as their value in animal production as non-antibiotic nutritional regulators. By improving animal health and reducing excessive drug use, residues, and risks of antimicrobial resistance at the source, BA-based precision nutrition may contribute to food safety and ecosystem health. Overall, this review positions BAs as key molecular hubs in One Health, linking host metabolism, gut microbiota, immune regulation, and the integrated health of humans, animals, and ecosystems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.